This study looked at many people who have chronic kidney disease. Some of these patients needed dialysis to clean their blood, while others did not. Doctors tested three new medicines called HIF-PHIs. These drugs are different from the older medicines usually used to help blood cells grow. The main goal was to see if these new drugs changed cholesterol levels in the blood.
The results showed that one of the new drugs, called roxadustat, worked well for lowering bad cholesterol. In the group of over ten thousand patients, the level of bad cholesterol went down by about sixteen milligrams per deciliter. This is a clear improvement for heart health. The total amount of cholesterol in the blood also went down by about twenty-five milligrams per deciliter. Even the level of fats called triglycerides dropped by nearly twenty milligrams per deciliter.
However, the study also found that this drug lowered good cholesterol by about five milligrams per deciliter. The other two new drugs, desidustat and molidustat, did not change cholesterol levels much. They did not lower bad cholesterol or good cholesterol in a meaningful way. This means roxadustat is the only one of the three that showed a strong effect on blood fats.
The most important part of the study was checking for safety. Doctors watched for heart attacks, strokes, and death from any cause. They found no difference between patients taking the new drug and those taking older medicines or a placebo. The risk of dying from any cause was the same for both groups. This is very good news because it means the drug does not increase the risk of serious events.
In short, this new medicine can help lower bad cholesterol in people with kidney disease. It does not seem to cause heart problems or death. Patients and doctors should talk to their healthcare team to see if this medicine is right for them. It offers a new option for managing blood fats without extra danger.